Ratings by Benchmark (Brice Jackson)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/10/2025 | Unicycive Therapeutics | UNCY | Maintain | Speculative Buy (Speculative Buy) |
|
Details | ||
| 9/6/2024 | Unicycive Therapeutics | UNCY | Maintain | Speculative Buy (Speculative Buy) |
|
Details | ||
| 11/13/2023 | Biofrontera | BFRI | Maintain | Buy (N/A) |
|
Details | ||
| 7/5/2023 | Biofrontera | BFRI | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2023 | Unicycive Therapeutics | UNCY | Maintain | Speculative Buy (N/A) |
|
Details | ||
| 1/31/2023 | Biofrontera | BFRI | Maintain | Buy (N/A) |
|
Details | ||
| 9/2/2022 | MANA Capital Acquisition Corp. | MANA | New Coverage | Speculative Buy (N/A) |
15.50 (0.60) |
-96.13% | Details | |
| 12/15/2021 | Biofrontera | BFRI | New Coverage | Buy (N/A) |
5.50 (1.11) |
-79.82% | Details | |
| 8/17/2021 | Unicycive Therapeutics | UNCY | New Coverage | Speculative Buy (N/A) |
2.64 (5.09) |
92.8% | Details | |
| 12/4/2019 | CNS Pharmasceuticals Inc. | CNSP | New Coverage | Speculative Buy (N/A) |
4.01 (5.09) |
26.93% | Details | |
| 2/27/2019 | Heska Corp. | HSKA | Downgrade | Hold (Buy) |
96.50 (119.99) |
24.34% | Details |
